Transforming growth factor beta (TGF-β) regulates a large number of biological processes, including proliferation, differentiation, immune response, and development. In addition, TGF-β plays important roles in some pathological processes, for instance, it is upregulated and activated in fibrosis and advanced cancer. Adenosine monophosphate-activated protein kinase (AMPK) acts as a fuel gauge that is activated when cells sense shortage of ATP and increase in AMP or AMP:ATP ratio. Activation of AMPK slows down anabolic processes and stimulates catabolic processes, leading to increased production of ATP. Furthermore, the functions of AMPK have been extended beyond energy homeostasis. In fact, AMPK has been shown to exert a tumor suppressive effect. Recent studies have demonstrated negative impacts of AMPK on TGF-β function. Therefore, in this review, we will discuss the differences in the biological functions of TGF-β and AMPK, and some pathological processes such as fibrosis, epithelial-mesenchymal transition (EMT) and cancer metastasis, as well as angiogenesis and heterotopic ossifications where TGF-β and AMPK exert opposite effects.
Introduction
Adenosine monophosphate-activated protein kinase (AMPK), consisting of three subunits, catalytic α subunit and regulatory β/γ subunits, is expressed in all eukaryotic cells. AMPK serves as a fuel gauge that senses energy crisis such as glucose deprivation, hypoxia, and ischemia [1, 2] . Under these circumstances, AMP is increased and binds to AMPK, leading to its activation. As AMPK is inhibited by excessive nutrients such as high levels of glucose and lipids, and is activated by metformin, a first line drug for type 2 diabetes, it is a well-received therapeutic target for metabolic disorders [3] . In fact, the activation of AMPK by pharmacological agents or exercise can alleviate hyperglycemia and hyperlipidemia and enhance insulin sensitivity [4, 5] . More than this, recent studies have delineated the roles of AMPK in various other processes such as fibrosis, epithelial-mesenchymal transition (EMT), cancer growth, and progression [3, 6, 7] .
Transforming growth factor beta (TGF-β) represents a superfamily comprising a large number of structurally related cell regulatory proteins, including the TGF-β subfamily, bone morphogenetic proteins (BMPs), activins/inhibins, growth differentiation factors (GDFs), Müllerian inhibitory factor (MIF), and the glial cell linederived neurotrophic factor (GDNF) [8] . These ligands bind to their cognate receptors, including seven TβRIs, also known as activin-like receptor kinases (ALKs: ALK1, ALK2, ALK3, ALK4, ALK5, ALK6, and ALK7), and five TβRIIs (TGFβR2, BMPR2, ACVR2, ACVR2B, and AMHR2) [9] . The TGF-β signaling pathways execute a variety of functions including cell growth, differentiation, organogenesis, angiogenesis, bone formation, fibrosis, tumorigenesis, and cancer progression.
Although developmental biology has not yet delineated direct connections between TGF-β and AMPK, recent studies have demonstrated that some pathological aspects implicated by TGF-β can be ameliorated by AMPK activators [10, 11] . Furthermore, it has been recently reported that AMPK negatively regulates the TGF-β signaling pathways [12] [13] [14] [15] . Thus, this review attempts to summarize the recent progress in the cross-talk between these two pathways and discuss the therapeutic potential of AMPK activators in the treatment of diseases in which dysregulated TGF-β signaling plays a pathogenic role.
Biological Functions of TGF-β and AMPK

TGF-β family in development and diseases
Regardless of a large family of TGF-β ligands and diversity of their receptors, the signaling flow is similar (Fig. 1) . In general, different TGF-β ligands act on specific pairs of type I and type II receptors. Upon ligand binding, the type II receptors phosphorylate the glycine-serine-rich region of the specific type I receptors (ALKs), despite that the ligand cross-activation exists depending upon ligand concentration and cell context [16] . The activated receptor I then phosphorylates canonical substrates, Smad2 or Smad3 (via ALK5) or Smad1/5/8 (via ALK1, ALK2, ALK4, and ALK7). In many circumstances, TGF-β ligands also activate non-canonical pathways including ERK1/2, JNK, PI3K, and Ras family small GTPases. Since the architecture of this pathway and mechanisms of regulation was described in details in other review articles of this review series [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] , it is not the focus here.
It has been shown that TGF-β signaling pathways play important roles in development, as genetic disruption of these pathways causes embryonic lethality owing to defects of organ development [8] . Mutations of members in the TGF-β signaling pathways have been found to be pathogenic factors for several human diseases. For example, heterozygous loss-of-function mutations of ALK1 or endoglin (ENG), a non-kinase accessory protein for ALK1, cause hereditary hemorrhagic telangiectasia, a familial human vascular syndrome that is characterized by the development of the fragile and direct connection between arteries and veins, or arteriovenous malformations [29, 30] . In addition, a rare autosomal genetic disease called fibrodysplasia ossificans progressiva (FOP) results from activating mutations of ALK2, among which the R207H mutation Figure 1 . Activation of TGF-β/BMP signaling events The simplified scheme of activation of TGF-β/BMPs signal transduction pathways is depicted here. Extracellular ligands bind to the type I (RI) and type II (RII) receptor complex, whereby RII phosphorylates RI, which is activated and in turn relay signals via the canonical pathway where RI phosphorylates R-SMAD (Smad2/3, substrates of ALK5; and Smad1/5/8, substrates of ALK1/2/4/7). The phosphorylated R-SMAD forms a complex with SMAD4, which translocates into the nucleus to regulate gene transcription. In addition, the TGF-β/BMPs regulate cellular events via noncanonical pathways including PI3K and MAPKs.
accounts for 95% of all cases [31] . Patients developed massive heterotopic ossification in soft tissues in the first decade of life and died around 40 years of age due to the restriction of respiration [31] . Furthermore, somatic mutations of Smad2/3/4 have been found in cancer, contributing to tumorigenesis [32] . All these mutations suggest tissue-specific functions of the TGF-β signaling paradigms.
The role of AMPK in energy homeostasis and diseases AMPK is a stress-activated protein kinase which is activated under shortage of ATP and increases in AMP or AMP:ATP ratio concurs (Fig. 2) . Canonically, its activation is initiated by binding of AMP to the γ subunit and followed by phosphorylation of Thr172 in the activation loop of the α subunit by upstream kinases including liver kinase 1 (LKB1), calmodulin-dependent protein kinase β (CaMKKβ), and TGF-β activated kinase 1 (TAK1) [1, 2] . Pharmacological agents that mimic calorie restriction to increase cellular AMP can activate AMPK, which include 5-amino-4-imidazolecarboxamide riboside-1-b-D-ribofuranoside (AICAR), metformin, phenformin, and berberine, etc. AMP plays two roles, preventing dephosphorylation of Thr172 and facilitating phosphorylation of this site by LKB1. Salicylate and A-769662 directly bind to the interface between α and β subunits and prevent dephosphorylation [2] . An additional mechanism of AMPK activation was recently identified in lysosomes, through sensing the absence of fructose-1,6-biphosphate (FBP), which is independent of AMP [33] . In the presence of glucose, FBP binds to aldose in the outer membrane of the lysosome, while in the absence of FBP due to lack of glucose, aldose dissociates from lysosome and is replaced by LKB1 to phosphorylate AMPK in situ.
Upon activation, AMPK phosphorylates a broad array of substrates. On the one hand, AMPK shuts down anabolic pathways that consume ATP, such as those for the synthesis of macromolecules, including protein, lipid, and glycogen. On the other hand, AMPK stimulates ATP generating programs like β-oxidation, glucose uptake, and cardiac glycolysis [3] . Simultaneously, AMPK activation can stimulate mitochondrial biogenesis to enhance the efficiency of energy production and consumption. As a result, the net effect of AMPK activation is to maintain ATP levels and restore energy balance. In response to energy stress, AMPK can enhance autophagy to initiate a self-protection mechanism [34] .
The functions of AMPK on energy homeostasis obtained with pharmacological agents are consolidated by mouse transgenic and knockout models [35] [36] [37] . Thus, ablation of AMPK was first made with the generation of catalytic subunit (α1 −/− and α2 −/− )-knockout mice, which shows distinct roles for AMPKα1 and AMPKα2 catalytic subunits in the control of energy metabolism. Although double knockout is lethal at~10.5 days post-conception, α1 or α2 single or tissue-specific knockout mice are viable and provide insightful information. Interestingly, AMPKα2 −/− but not AMPKα1 −/− mice are resistant to the hypoglycemic effects of AICAR [36, 37] , suggesting that the AMPKα2 isoform is the main contributor to glucose metabolism during AMPK activation by AICAR at the whole-body level. Furthermore, whole-body deletion of AMPKα1 has no detectable metabolic phenotype, whereas AMPKα2 deletion results in mild insulin-resistance and impaired glucose tolerance associated with a defect of insulin secretion [36, 37] . These findings are intriguing because both catalytic subunits are present in skeletal muscle and liver that are essential for the regulation of glucose homeostasis. AMPK mainly participates in the regulation of energy homeostasis in metabolic syndrome; however, recent studies on AMPK have extended to other areas such as tissue fibrosis, EMT, and cancer progression. Although genetic evidence is still short in support of direct implication of AMPK in these biological processes, a plenty of pharmacological and biochemical data indicate that AMPK functions as a safeguard to monitor and correct alterations that require energy and/or may cause energy imbalance. For example, mitochondrial reprogramming during EMT in cancer cells changes glucose utilization from mitochondrial oxidation to glycolysis (namely, Warburg effect). This reprogramming can be reversed by activation of AMPK [38, 39] .
Opposing Effects of TGF-β and AMPK in Pathological Processes
Fibrosis
Fibrosis is a severe pathological stage of organ dysfunction which results in high morbidity and motility. It occurs as a result of imbalanced extracellular matrix (ECM) deposition and degradation [40] . Fibrosis is seen in pulmonary fibrosis, liver cirrhosis, diabetic nephropathy, glomerulonephritis, myocarditis, congestive heart failure, hypertrophic scars, and systemic sclerosis, etc. [41, 42] . A critical step of fibrosis is the formation of myofibroblasts, which phenotypically express the contractile protein α-smooth muscle actin (α-SMA) [43] . Upon biological or environmental insults, quiescent fibroblasts proliferate and differentiate into proto-myofibroblasts which express actin filaments that extend from a focal adhesion complex, and ED-A (extra domains-A) fibronectin, a pivotal element for myofibroblast Figure 2 . Activation of AMPK and downstream events AMPK is activated by the following mechanisms: (1) pharmacological agents, hormones, adipokines, cytokines, and energy stress increase intracellular level of AMP which binds to the γ subunit of AMPK, inducing a conformational change, (2) aspirin/salicylate and A796692 directly bind to amino acids between α and β subunits, (3) glucose deprivation diminishes fructose-1,6-bisphosphate (FBP), leading to replacement of aldolase by LKB1 in lysosome where AMPK is phosphorylated and activated. The latter two occur in the absence of AMP.
In addition to binding of allosteric activators, phosphorylation of Thr172 by LKB1 or CaMKKβ plays an essential role for maximal activation of AMPK. Upon activation, AMPK implements various functions, including inhibition of anabolic processes, stimulation of catabolic processes (fatty acid oxidation, cardiac glycolysis, and autophagy) and mitochondrial biogenesis, and inhibition of cancer cell growth, EMT, and fibrosis. Of note, the functions of AMPK are more than those depicted in this diagram.
differentiation. The proto-myofibroblasts then further differentiate into matrix-secreting myofibroblasts. Excessive ECM secretion and deposition results in scarring and thickening of the affected tissue, and interferes with tissue and organ homeostasis. Fibrosis is primarily driven by inflammatory cytokines including members of the TGF-β subfamily, especially TGF-β1 [10, 44, 45] . Many of them are secreted by inflammatory cells infiltrating toward damaged tissues. The TGF-β ligands are increased in fibrotic diseases and trapped within the accumulating matrix, thereby accelerating the profibrotic response. Activation of the TGF-β signal transduction pathway regulates the expression of many profibrotic genes, including various collagens [46] , plasminogen activator inhibitor-1 (PAI-1) [47] [48] [49] , various proteoglycans [50] [51] [52] , integrins [53] , connective tissue growth factor (CTGF) [54] , and matrix metalloproteases (MMPs) [55] .
In fibrotic diseases, the effects of TGF-β1 are mainly mediated through the activation of Smad3, which promotes myofibroblast transdifferentiation (MFT) and matrix preservation. Thus, oral administration of a small molecular inhibitor of ALK5 inhibits TGF-β1-induced pulmonary fibrosis in a rat model [56] . Smad3-null mice exhibit resistance to bleomycin-induced pulmonary fibrosis in experimental models [57] . Similarly, cardiac fibrosis, renal interstitial fibrosis, and dermal fibrosis are all attenuated in Smad3-deficient animal models. A crucial effector of TGF-β-induced fibrosis is CTGF. TGF-β induces the expression of CTGF in fibroblasts, which in turn promotes myofibroblast differentiation and collagen synthesis [57] . Moreover, CTGF binds to TGF-β directly and thus enhances its activity and expressions of both TβRI and TβRII [58] . Therefore, accumulating evidence suggests that TGF-β may serve as a promising therapeutic target for fibrosis.
In light of the profound effects of TGF-β on fibrosis, a number of approaches have been explored to target TGF-β signaling pathways, including ligand and receptor-specific antibodies, decoy receptors, and small inhibitory compounds [59] . However, no effective therapy has so far gone through phase III clinical trial. Therefore, it is still a challenging task to develop novel inhibitory approaches.
The inhibitory effects of AMPK are reproducibly observed in fibrosis of the liver, heart, kidney, and lung, which possibly underlie multiple mechanisms, among which the cross-talk with TGF-β signaling plays an important role (Fig. 3) . It was reported that TGF-β1 diminishes phosphorylation of Thr172, concurrently with increased fibrosis [60] . In contrast, pharmacologic activation of AMPK is able to reverse the effects of TGF-β1 on fibrogenic responses, while inhibition of AMPK imitates or enhances the effect of TGF-β1 [60] . A recent study has demonstrated that activation of AMPK by metformin inhibits the production of type I collagen in fibroblast cells in response to TGF-β1; however, AMPK does not have an impact on Smad3 phosphorylation but rather blunt the increased expression of CTGF [61] . Treatment of cells with Compound C, an inhibitor of AMPK, reverses the effect of metformin on the TGF-β1-triggered expression of CTGF, and type I collagen. This study suggests that activated AMPK first interferes with TGF-β1-induced transcription of CTGF, which then leads to suppression of type I collagen expression [61] . In another study, hepatocyte growth factor (HGF) was shown to inhibit TGF-β1-induced ECM deposition and myofibroblast differentiation in Achilles tendon of rats [62] . The effect of HGF was effectively attenuated by Compound C [63] . Similarly, blockade of the AMPK signaling pathway via AMPKα1 siRNA disrupts the inhibitory effect of HGF on the TGF-β1-induced fibrogenic program, whereas expression of the constitutively active mutant of AMPKα1 mimics the effect [63] . In addition, an in vitro study has documented that AICAR leads to the inhibition of the collagen I production by hepatic stellate cells (HSCs) [64] . AICAR was shown to inhibit the interaction between transcriptional coactivator p300 and Smad3, accompanied by the reduction of Smad3 acetylation. Concomitantly, the interaction between AMPK and p300 was promoted.
In addition, AMPK activators, such as metformin, berberine, and adiponectin, have been shown to inhibit the expressions of fibrogenic genes, concurrently with suppression of the proliferation of fibroblast cells and their transdifferentiation into myofibroblasts in vitro [64] [65] [66] [67] [68] [69] [70] . Studies using animal models have revealed that metformin prevents cardiac fibrosis [7, 66, 67] . Furthermore, studies in patients have shown that metformin alone or in combination with N-acetylcysteine ameliorates non-alcoholic hepatic steatosis and liver fibrosis [6, 71, 72] . Whether TGF-β is involved in this sort of fibrosis is not clear. In any event, targeting AMPK may provide a potential therapeutic approach for the treatment of fibrosis.
Epithelial-mesenchymal transition
EMT plays important roles in development, wound healing and pathological processes including fibrosis and cancer metastasis [11] . The cells of a developing blastocyst exhibit epithelial characteristics and undergo transdifferentiation into multiple tissues and organs [73] . Thus, EMT is a developmental transdifferentiation process coupled with mesenchymal-epithelial transition (MET), both of which are essential for the formation of tissues and organs. Such developmental EMT is termed as type I EMT. The type II EMT operates during wound healing and tissue fibrosis, while the type III EMT participates in cancer progression [11] . All these different types of EMTs are initiated by physiological or pathological activation of various signaling pathways such as Wnt, Notch, receptor tyrosine kinase, cytokine receptor-JAK-STAT, hedgehog, hippo, nuclear receptor, and TGF-β pathways.
TGF-β exerts profound effects on EMT and participates in almost all essential steps (Fig. 4) [11, 74] . Although many signaling pathways are involved, it has been shown that TGF-β regulates expression of many growth factors, cytokines and even some of their receptors to promote the EMT program. Furthermore, major
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Pathological angiogenesis Cancer Ectopic bone formation Figure 3 . TGF-β-regulated events Disorders where TGF-signaling pathway is dysregulated and contributes to the pathogenesis are summarized here.
(1) TGF-β is upregulated and activated in advanced cancer, EMT, and fibrosis. transcription factors (e.g. Snail1/2, Zeb1/2, and Twist1/2) essential for EMT are either regulated by TGF-β or interacting partners for Smad2/3 [11] . The hallmarks of EMT are the destruction of E-cadherin and replacement with N-cadherin in the adherens junctions, and the expression of new cytoskeletal filaments such as intermediate filaments containing vimentin or specific cytokeratins. TGF-β regulates cadherin switch via different mechanisms. First, TGF-β upregulates the transcriptional factor high mobility group A2 (HMGA2) as well as Snail1 and ZEB1. Smads and Snail1 form a complex which binds to the silence element of E-cadherin. Second, HMGA2 recruits a DNA methyltransferase, DNMT3A, to the E-cadherin gene to silence the gene expression. Third, Snail1 recruits histone modification enzymes to evoke repressive and active marks via methylation and deaceytylation of the promoter region of E-cadherin to silence its transcription [75] . Upon degradation of E-cadherin and suppression of its expression, β-catenin is released from adhering complexes and activated by other signaling pathways, such as Wnt and PI3K/Akt, which then participates in EMT. Simultaneously, TGF-β via regulation of multiple transcription factors induces the expressions of N-cadherin, vimentin, and fibronectin for mesenchymal program [75] . Recent studies have delineated an inhibitory role of AMPK in EMT. Thus, metformin and other AMPK activators may inhibit EMT via multiple mechanisms, for instances, through inhibition of TGF-β, FoxoM1 (Forkhead box protein M1), Akt-MDM2 (mouse double minute 2 homolog)-Foxo3a, IL6, and miR-3a [12, [76] [77] [78] [79] [80] [81] [82] .
Cancer progression and metastasis
It has been known that TGF-β acts as both a tumor suppressor and a tumor promoter [83] . In benign or early-stage tumors, TGF-β induces growth arrest. In advanced tumors, the level of TGF-β is positively associated with tumor size, invasiveness and dedifferentiation, and the activity of the TGF-β signaling pathway is enhanced, which in turn promotes cancer progression [83] [84] [85] . Hence, alteration of TGF-β level can serve as a useful prognostic biomarker and predictor of recurrence after initial or failed therapy [86] [87] [88] . In fact, the serum level of TGF-β increases in many types of cancers [89, 90] . The level of TGF-β decreases with surgical removal of cancer and increases in recurrent cancer [91] . Increased secretion of TGF-β from tumors renders them resistant to chemotherapy, while antagonizing TGF-β with neutralizing antibody increases chemotherapeutic sensitivity [92] [93] [94] . The mechanism of promoting tumor progression by TGF-β is complex. First, TGF-β regulates EMT, which is critical for the formation of cancer stem cells and cancer metastasis [95] . Second, TGF-β inhibits an immune response, allowing cancer cells to escape immune surveillance [96] . Third, TGF-β regulates the expressions of MMPs in either cancer cells or resident stroma cells, which then activate latent TGF-β in the ECM, together with facilitating cancer progression [97] . Fourth, TGF-β stimulates angiogenesis, favoring cancer growth, and metastasis in advanced stages [30, 44] .
We have shown that AICAR inhibits proliferation of prostate cancer cells, concurrently with the inhibition of key enzymes for biosynthesis of fatty acid and protein [98] . A retrospective investigation showed that the cancer incidence in the patients with type 2 diabetes who are treated with metformin as a glucose-lowering drug is significantly lower than those taking other medicine [99] . Since then, the role of AMPK in cancer has attracted great attention and thus far, a large number of studies have confirmed the tumor suppressive function of AMPK [100] [101] [102] . Consistently, loss-of-function mutations of LKB1, an upstream kinase of AMPK, has been found in many types of cancer and cancer cells deficient in LKB1 are resistant to chemotherapy [101, 103] . A recent study has revealed that LKB1 suppresses SMAD4 expression, leading to the inhibition of tumor heterogeneity and EMT [104] . Second, studies have also shown that inactivation of AMPK by expressing dominant negative mutants of AMPK or small interference RNA (siRNA) enhances malignant behaviors of cancer cells, such as increased invasion and EMT [14, 105] . Third, a phospho-Thr172 signal of AMPK, an indicator of its activation state, is lower in human breast cancer area than that in adjacent normal tissues and treatment of breast cancer with metformin as a neoadjuvant chemotherapy in diabetes patients exhibits better pathologic complete response [106, 107] . Intriguingly, Hirsch et al. [108] reported that cancer stem cells are especially sensitive to metformin treatment. The inhibition of cancer cell progression by AMPK underlies complex mechanisms, such as activation of p53, p27, and Foxo3a, inhibition of mTOR and TGF-β signaling, and reprogramming of metabolic profiles, which switches the Warburg effect to glucose oxidation through mitochondria [38, 39, 101] .
Possible involvement of the cross-talk between AMPK and TGF-β in other diseases
We have recently investigated if AMPK has an effect on the BMP signal transduction pathways. Two lines of investigations were performed. First, human umbilical vein endothelial cells (HUVECs) were treated with metformin and other pharmacological activators, followed by BMP9 treatment. The results revealed that activation of AMPK inhibited Smad1/5 phosphorylation and attenuated tube formation of HUVECs induced by BMP9 [15] . This event could be mimicked by the active mutant of AMPKα1 expression and blocked by the dominant negative mutant of AMPKα1. The constitutively active mutant of ALK1 stimulated tube formation, which was abolished by metformin. The effects of metformin on angiogenesis/ neovascularization were observed using Matrigel plug analysis and choroidal neovascularization model in mice. As upregulation of ALK1 signaling has been reported to be associated with angiogenesis in cancer, the finding of AMPK inhibition of ALK1-associated angiogenesis may pave a road for cancer therapy.
A second line of investigation was to assess the role of AMPK in ALK2 signaling, which is often associated with heterotopic ossification [13] . We focused on FOP by using fibroblast cells containing the R206H mutant of ALK2 obtained from a FOP patient. We found that metformin suppresses Smad1/5 phosphorylation under the basal or BMP4-treated condition in association with suppression of osteogenic differentiation. These results provide us with a clue for therapy of FOP and other heterotopic bone formation. In the meantime, they are intriguing and perplexing because it seems that AMPK inhibits all ALKs-mediated signaling events.
Possible Mechanisms of AMPK Regulation of TGF-β Signaling
Multiple mechanisms may account for AMPK inhibition of TGF-β-mediated signaling events (Fig. 4). (1) AMPK suppresses the transcription of TGF-β1 [14] . (2) Regulation of stability of ALKs. Our studies have demonstrated that AMPK upregulates Smad6, an inhibitory Smad, and Smurf1, an E3 ubiquitin ligase, specific for proteosomal degradation of ALK1/2 and RUNX2 (Runt-related transcription factor 2) [13, 15] . Transfection of siRNA for Smad6 or Smurf1 prevents metformin-induced proteosmal degradation of these proteins. Therefore, the AMPK activation-induced suppression of Smad1/5 phosphorylation seemingly occurs through degradation of ALK1/2. (3) R-SMAD phosphorylation-dependent event in the absence of the receptor degradation. It has been shown that AMPK activation decreases the level of phosphorylation of R-SMADs [109] . An early study has reported that metformin reduces Smad3 phosphorylation in response to TGF-β1, concurrently with inhibition of the nuclear translocation of Smad3 and its transcriptional activity in adult mouse cardiac myocytes [7] . Similar findings were also obtained by us in cancer cells [110] . (4) The p300-dependent event. As noted earlier in this article, AMPK could directly bind to p300 and compete off Smad3 [64] . The p300 acetylates Smad3, leading to an increase in the transcription activity of the latter. (5) R-SMAD-dependent but a phosphorylation-independent event. It has been shown that AMPK inhibits MFT induced by TGF-β, which is independent of Smad3 phosphorylation and nuclear translocation [111] . Suppression of Smad3-mediated signaling by AMPK occurs at the transcriptional level, as reflected by the reporter gene activity containing the PAI-1 promoter [112] . Which of these mechanisms prevails is probably related to cell types.
Conclusions
TGF-β represents a large family of extracellular regulators with similar structure and elicits a great diversity of cellular functions. Despite their essential roles in physiology, dysregulation of the signal transduction pathways of TGF-β family has been implicated in various diseases, presenting them as therapeutic targets. However, thus far, few of therapeutic drugs targeting the TGF-β signaling pathways are available for the treatment of diseases. AMPK is a fuel-sensing enzyme whose major function is to regulate energy homeostasis, so as to protect cells. Recent studies have illustrated the negative effect of AMPK on TGF-β signaling and their opposing effects on several disease conditions such as cancer, fibrosis, angiogenesis, and ectopic bone formation. As many activators of AMPK have already been used in clinics for the treatment of diabetes and obesity, re-tasking them to the therapy of the diseases where TGF-β has pathogenic roles would provide us with a new direction for patient care. However, the mechanisms by which AMPK regulates the TGF-β signaling events are still not completely understood, and further investigations are required to unravel these mechanisms.
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